Who Paid My Doc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])
Research payments
$374,176
Through program year 2025, $374,176 in research payments was reported against A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]), across 25 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $374,176 | 25 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Priscilla Chee Loma Linda, CA Named on 3 payments
- Robert Carlile Summerville, SC Named on 2 payments
- Jose Ferreira Tampa, FL Named on 2 payments
- Barry Vaught Crab Orchard, WV Named on 2 payments
- Marc Disabella Washington, DC Named on 1 payment
- Christina Szperka Philadelphia, PA Named on 1 payment
- Alma Bicknese Chicago, IL Named on 1 payment
- Gina Jones Topeka, KS Named on 1 payment
- Ryan Williams Norfolk, VA Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.